Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer

PLoS Negl Trop Dis. 2018 Aug 13;12(8):e0006728. doi: 10.1371/journal.pntd.0006728. eCollection 2018 Aug.

Abstract

ClinicalTrials.gov NCT03474198, NCT01659437.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use
  • Buruli Ulcer / drug therapy*
  • Clofazimine / administration & dosage
  • Clofazimine / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Mice
  • Mice, Inbred BALB C
  • Mycobacterium ulcerans / drug effects*
  • Rifamycins / administration & dosage
  • Rifamycins / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Rifamycins
  • Clofazimine

Associated data

  • ClinicalTrials.gov/NCT03474198
  • ClinicalTrials.gov/NCT01659437